Vaccine Company

About Vaccine Company

Vaccine Company, Inc. is a pre-clinical-stage biotechnology enterprise dedicated to developing advanced therapies and preventative solutions for complex infectious diseases. Founded in 2022 and headquartered in Bethesda, Maryland, the company engineers novel vaccine candidates to address critical unmet medical needs, particularly focusing on highly prevalent viral pathogens. Its flagship program is a Phase 1-ready multivalent vaccine designed to prevent Epstein-Barr Virus (EBV) and the serious long-term conditions associated with its infection, such as infectious mononucleosis.

The company primarily operates within the B2B and B2G sectors, collaborating with major pharmaceutical partners, global health organizations, and government research agencies. As a pre-commercial entity, Vaccine Company does not yet generate product revenue; its operations are sustained through significant venture capital backing and substantial federal grants, such as funding from the Advanced Research Projects Agency for Health (ARPA-H). By demonstrating robust preclinical success, the firm positions its proprietary technologies for eventual commercial manufacturing and global distribution through strategic acquisitions and partnerships.

A key differentiator for Vaccine Company is its proprietary In Vivo Nanoparticle (IVN) technology platform. This advanced engineering approach is designed to combine the rapid adaptability of mRNA therapeutics with the durable, highly immunogenic antigen display characteristic of virus-like particle (VLP) vaccines. By avoiding the complex and costly manufacturing burdens traditionally associated with VLP production, the IVN platform enables the scalable creation of stable, multivalent vaccines. Driven by a pipeline that also includes candidates for pathogens like MERS-CoV, the company represents a significant leap forward in modern vaccine science and global health resilience.